Gilead Sciences Financial Statements
11,610 Followers
Gilead Sciences Financial Overview
Gilead Sciences's market cap is currently ―. The company's EPS TTM is $3.279; its P/E ratio is 19.76; and it has a dividend yield of 4.54%. Gilead Sciences is scheduled to report earnings on October 27, 2022, and the estimated EPS forecast is $1.55. See an overview of income statement, balance sheet, and cash flow financials.
| Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 6.26B | $ 6.59B | $ 7.24B | $ 7.42B | $ 6.22B |
| Gross Profit | $ 4.82B | $ 5.17B | $ 4.62B | $ 6.20B | $ 4.83B |
| EBIT | $ 1.75B | $ 86.00M | $ 997.00M | $ 3.69B | $ 2.07B |
| EBITDA | $ 2.27B | $ 611.00M | $ 1.53B | $ 4.21B | $ 2.59B |
| Net Income Common Stockholders | $ 1.14B | $ 19.00M | $ 382.00M | $ 2.59B | $ 1.52B |
| Balance Sheet | |||||
| Cash, Cash Equivalents and Short-Term Investments | $ 5.66B | $ 5.33B | $ 6.52B | $ 5.74B | $ 6.53B |
| Total Assets | $ 62.87B | $ 63.08B | $ 67.95B | $ 67.10B | $ 67.98B |
| Total Debt | $ 26.22B | $ 26.21B | $ 26.68B | $ 26.69B | $ 30.17B |
| Net Debt | $ 20.55B | $ 20.88B | $ 20.16B | $ 20.95B | $ 23.65B |
| Total Liabilities | $ 42.66B | $ 43.16B | $ 46.89B | $ 45.63B | $ 48.27B |
| Stockholders Equity | $ 20.24B | $ 19.93B | $ 21.07B | $ 21.47B | $ 19.70B |
| Cash Flow | |||||
| Free Cash Flow | $ 1.66B | $ 1.59B | $ 3.05B | $ 3.11B | $ 2.20B |
| Operating Cash Flow | $ 1.80B | $ 1.84B | $ 3.21B | $ 3.25B | $ 2.32B |
| Investing Cash Flow | $ -308.00M | $ -1.07B | $ -278.00M | $ -234.00M | $ -577.00M |
| Financing Cash Flow | $ -1.00B | $ -1.79B | $ -1.94B | $ -3.53B | $ -931.00M |